Search research articles
Contact Us
Filters
Showing results (61-70 of 144) with videos related to
Page
of 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 21, 2007
Progression-free survival is a surrogate for survival in advanced colorectal cancer
Marc Buyse, Tomasz Burzykowski, Kevin Carroll, et al.
Lancet (London, England)
|
July 22, 2014
Preoperative chemotherapy for non-small-cell lung cancer--authors' reply
Sarah Burdett, Larysa H M Rydzewska, Jayne F Tierney, et al.
The Lancet. Oncology
|
October 19, 2007
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data
Karim Fizazi, Aurelie Le Maitre, Gary Hudes, et al.
Cancer Treatment and Research Communications
|
December 24, 2022
Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment
Eugénie Rigault, Benjamin Lacas, Olivier Glehen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 2, 2017
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
Francesco Facchinetti, Maria Virginia Bluthgen, Gabrielle Tergemina-Clain, et al.
BMC Cancer
|
August 8, 2018
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973)
Diane Goéré, Jean-Pierre Pignon, Maximiliano Gelli, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 22, 2011
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer
Benjamin Besse, David Planchard, Anne-Sophie Veillard, et al.
Radiation Oncology (London, England)
|
September 28, 2011
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival
Lucie Oberic, Frédéric Viret, Charlotte Baey, et al.
BMJ Open
|
March 15, 2013
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials
Silvy Laporte, Pierre Squifflet, Noémie Baroux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2011
Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data
Jean Bourhis, Pierre Blanchard, Emilie Maillard, et al.
Page
of 15
Search research articles
Search
Showing results (61-70 of 144) with videos related to
Sort By:
Page
of 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 21, 2007
Progression-free survival is a surrogate for survival in advanced colorectal cancer
Marc Buyse, Tomasz Burzykowski, Kevin Carroll, et al.
Lancet (London, England)
|
July 22, 2014
Preoperative chemotherapy for non-small-cell lung cancer--authors' reply
Sarah Burdett, Larysa H M Rydzewska, Jayne F Tierney, et al.
The Lancet. Oncology
|
October 19, 2007
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data
Karim Fizazi, Aurelie Le Maitre, Gary Hudes, et al.
Cancer Treatment and Research Communications
|
December 24, 2022
Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment
Eugénie Rigault, Benjamin Lacas, Olivier Glehen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 2, 2017
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
Francesco Facchinetti, Maria Virginia Bluthgen, Gabrielle Tergemina-Clain, et al.
BMC Cancer
|
August 8, 2018
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973)
Diane Goéré, Jean-Pierre Pignon, Maximiliano Gelli, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 22, 2011
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer
Benjamin Besse, David Planchard, Anne-Sophie Veillard, et al.
Radiation Oncology (London, England)
|
September 28, 2011
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival
Lucie Oberic, Frédéric Viret, Charlotte Baey, et al.
BMJ Open
|
March 15, 2013
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials
Silvy Laporte, Pierre Squifflet, Noémie Baroux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2011
Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data
Jean Bourhis, Pierre Blanchard, Emilie Maillard, et al.
Page
of 15